

# TRANSPLANTATION IMMUNOLOGY.

## Learning Objectives.

- Describe the genetic variation in transplantation
- Understand the immunological barriers that must be considered in transplantation.
- Understand the basis of rejection of transplants
- Describe donor tissues and privileged organs in transplantation.

# Introduction.

- **Transplantation** is the introduction of biological material - organs, tissue, cells, fluids - into an organism.
- **We can distinguish 3 critical relationships between the transplanted material and the recipient.**
- **syngeneic** transplants - from genetically identical individuals, usually the **same individual** (*these are similar to grafts between identical twins or isogenic strains of experimental animals*). Referred to as *autologous* in the ABO blood groups, *skin grafts*.
- **allogeneic** transplants - from one individual to another of the **same species**
- **xenogeneic** transplants - between individuals of **different species**.

- Unsurprisingly syngeneic transplants (same individuals) do not usually generate any immunological problems, but **allogeneic** and **xenogeneic** transplants are almost always destroyed by immunological processes unless some action is taken to impair the immunological process.

- Basically therefore transplantation presents 2 key problems.
  - Genetic variation between donor and recipient.
  - Immunological recognition of the variation.

# 1. Genetic variation between donor and recipient.

- Genetic variation between individuals that results in **protein sequence differences** is at the heart of the transplant problem.
- In an essentially out-bred species like *Homo sapiens* the extent of this **allelic polymorphism** is considerable.
- Obviously the variation is even greater between individuals from different species.

## 2. Immunological recognition of the variation.

- Genetic differences between donor and recipient are only of significance in transplantation if they cause **incompatibility**.
- Almost ubiquitous in allogeneic transplants is **immunological rejection**.
- Early experimental work on allotransplantation in mice identified a very clear distinction between one chromosomal region and the remainder of the genome.

- Non-identity at this special region always led to **very rapid rejection of the transplanted** tissue, even if this was the only genetic difference between the donor and recipient.
- This region was therefore termed the **Major Histocompatibility Complex (MHC)**.
- MHC, which exists in all vertebrates is **highly polymorphic**, so that in out-bred populations 2 individuals will almost certainly differ at this region unless they are monozygotic.



- However the parallel is NOT true, that is, even **if identical at the MHC**, transplants between individuals are likely to be rejected due to **minor histocompatibility loci**.
- The key distinction is that **individually** these **minor H loci** are less 'strong' and in particular the strength varies between allelic differences.

## Recognition and rejection mechanisms.

- There are 3 basic types of 'recognition' which allows the host to know that the transplanted tissue is foreign.
- recognition by Antibody
- recognition of foreign MHC by T cells (**direct recognition**)
- recognition of minor H loci by T cells (**Indirect recognition**).

- As implied above these 3 recognitions may lead to very different time scales of destruction of the transplanted cells/tissue and trigger distinct effector mechanisms. We distinguish 3 types of rejection.

## Types of rejection.

- Hyper-acute rejection
- Acute rejection
- Chronic rejection

## 1. Hyperacute rejection.

- Occurs very rapidly, resulting in **necrosis of the transplanted tissue within minutes or a few hours of contact.**
- It always results from the reactivity of the donor cells with **pre-existing antibody.**
- The most common situation in which this occurs is in ABO blood group incompatible transplants, therefore let us briefly review the ABO system.

# Blood Groups.

- Blood groups arise from **genetic variations within a species**. Blood transfusion is the oldest form of transplantation and today we should be careful to distinguish what component of blood we are transplanting; **what we call blood groups are genetically variable (polymorphic) structures present on red blood cells**.
- It is important to note that **some of these structures are only present on red blood cells and thus incompatibility at these loci only affects the transplantation of RBC** (blood transfusion), whereas others are present on many tissue cells and therefore affect other types of transplantation.

## Non-ABO antibodies can also cause hyperacute rejection.

- These could be from previous transplants (transfusions)
- Particular problems in xenotransplants
  - humans lack Gal alpha 13 Gal structures **and** make natural antibody to this (**both IgG and IgM**).
  - many species express this structure in abundance on their cell surfaces (e.g Pigs).
  - Transplants from one species to another where there is natural antibody are termed **discordant**.

## 2. Acute Graft Rejection

- This is the main immunological barrier to allotransplantation (same species, **BUT** different individuals).
- It is caused by **T cell recognition of the transplanted tissue.**
- It is not a significant problem in red cell transfusion
  - a. because the cells survive only short periods
  - b. human rbc do not express MHC antigens.
- There are 2 quite distinct modes of recognition



## A. Direct recognition of allo MHC.


As referred to earlier, experimental transplantation showed that a single major gene cluster, the MHC, had a dominant role in histocompatibility.

In the context of transplantation the key attributes of the MHC are

- rapid rejection of MHC non-identical transplants
- reproducible, consistent rejection rates.

# modes of recognition: **Direct recognition of allo MHC**

## Direct recognition of donor MHC molecules




- **Why do the products of the MHC cause such reproducible and rapid graft rejection?**

**The basic answer to this question is that naive individuals have high-frequency of T cells reactive with alloMHC products. More complex is to explain why this high frequency exists.**

- It is undoubtedly the result of T cell receptors being MHC binding.

## B. Indirect recognition of minor transplantation antigens.

### Indirect recognition of minor H antigens



MHC identical grafts are still rejected acutely by T cell dependent mechanisms.

- Minor transplantation antigens are proteins which vary in sequence and where one (at least) of the allomorphs is found in a peptide which binds to the MHC of the recipient.
- In the case of indirect recognition, MHC sharing between donor and recipient increases the reactivity as donor dendritic cells can prime recipient T cells for minor H peptides bound to shared MHC
- activated T cells can be triggered by donor tissue cells (usually class I expressing)

## Properties of minor antigens

- rejection is slower than for MHC
- it is additive, however; thus many minor differences combine to give rapid rejection
- rejection times (in experimental grafts) are more variable and strength is allele specific.

### 3. Chronic rejection.

- In stark contrast to the considerable progress in the management of acute rejection (see Immunosuppression, below) essentially no improvement in treatment in past 25 years has made a significant impact on the long-term loss of transplanted organs through chronic rejection.
- Possibly in part this is because the mechanism(s) of chronic rejection are still obscure.

## Particular transplant situations.

### 1. Privileged sites.

- Transplants at certain anatomical sites are generally accepted without any immune rejection. The most important of these is the **cornea**.
- The absence of lymphatic drainage is probably the critical common factor.
- (some sites also lack vascularisation).



## 2. Vascularised solid organs.

- kidney
- lung
- liver
- heart
- pancreas

### 3. Haemopoietic stem cell transplants

- Often previously called bone marrow transplants, now renamed as source is frequently blood.
- 3 sources of stem cells are used, listed in order of decreasing mature T cell contamination
  - peripheral blood (enriched by cytokine administration)
  - bone marrow
  - cord blood